Anika Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -14.58%. Anika Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 1.45.
Anika Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -10.06%.
Anika Therapeutics ROE % Adjusted to Book Value Related Terms
Anika Therapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics ROE % Adjusted to Book Value Chart
ANIK vs LFCR, DERM, ASRT: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -10.06% mean?
Anika Therapeutics (ANIK) has a ROE % Adjusted to Book Value of -10.06% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' ROE % Adjusted to Book Value too high?
Anika Therapeutics' current ROE % Adjusted to Book Value is -10.06%. Overall, Anika Therapeutics has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' ROE % Adjusted to Book Value compare to LFCR and DERM?
Anika Therapeutics' ROE % Adjusted to Book Value of -10.06% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current ROE % Adjusted to Book Value is -10.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (ANIK) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.58, compared to a current price of $16.30 — trading 20.8% below its estimated fair value. The current ROE % Adjusted to Book Value is -10.06%. Anika Therapeutics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Anika Therapeutics (ANIK), the current ROE % Adjusted to Book Value is -10.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (ANIK) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued.
The current stock price of $16.30 is trading 20.8% below its estimated GF Value™ of $20.58.
GuruFocus considers Anika Therapeutics to be Modestly Undervalued.
Key valuation signals for ANIK:
ROE % Adjusted to Book Value: -10.06%
GF Value™: $20.58 vs. price of $16.30 (20.8% below fair value)
No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
64GF Score
Get the complete analysis for ANIK
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIK has been successfully added to your 
